HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Nektar Therapeutics Reports Inducement Grants

Created at 3 Jun · 8:18 PM2 sources2 events
IN SHORT

Nektar Therapeutics announced that its Organization and Compensation Committee granted non-qualified stock options to purchase 11,900 shares of its common stock on May 20, 2026. The grants were made under Nasdaq Listing Rule 5635(c)(4).

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

11,900shares of common stock granted via stock options
May 20, 2026date of stock option grants

Who's Involved

Nektar Therapeutics
Biopharmaceutical company announcing stock option grants
Organization and Compensation Committee of Nektar's Board of Directors
Granted non-qualified stock options

↳ Why This Matters

This announcement details equity compensation awards, which can impact shareholder value and dilute existing ownership. Such grants are often used to attract and retain key personnel.

Key facts

  • Nektar Therapeutics granted stock options on May 20, 2026.
  • The options are for 11,900 shares of common stock.
  • The grants were made under Nasdaq Listing Rule 5635(c)(4).

Nektar Therapeutics (NASDAQ: NKTR) announced on June 3, 2026, that its Organization and Compensation Committee granted non-qualified stock options on May 20, 2026. These options allow for the purchase of an aggregate of 11,900 shares of the company's common stock. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Frequently asked questions

Nektar Therapeutics announced that it granted non-qualified stock options to purchase 11,900 shares of its common stock.

The stock options were granted on May 20, 2026.

The grants were made under Nasdaq Listing Rule 5635(c)(4).

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence
CME Headlines
  • New Product Summary: Initial Listing of Fifty-Five (55) Single Stock Futures Contracts — Effective July 27, 2026
    27 Jul · 4:32 PM
  • New Product Summary: Initial Listing of Twenty-Two (22) Micro Single Stock Futures Contracts - Effective July 27, 2026
    27 Jul · 4:11 PM
  • Initial Listing of Additional Event Contract Swaps on Pro Golf Tournaments
    9 Jul · 9:41 AM

How It Developed

3 Jun · 8:15 PM
Nektar Therapeutics announced inducement grants of 11,900 stock options on May 20, 2026.
PRN | All News Releases via PiQSuite
3 Jun · 8:01 PM
Edgewise Therapeutics announced inducement grants on May 29, 2026, as permitted by Nasdaq Listing Rules.
PRN | All News Releases via PiQSuite

Sources

T1
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesm.piqsuite.com
T1
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)m.piqsuite.com

Related Stories

JPMorgan Hires Michael Flynn to Lead New Small-Cap Banking Business
8 Jul · 3:03 PM
SK Hynix $28B ADR bookbuild closes Wednesday amid strong demand
8 Jul · 7:57 AM
Webull launches commission-free US stock trading in Japan
8 Jul · 9:40 PM
SK Group chief to attend SK hynix ADR listing debut on Nasdaq
8 Jul · 11:55 PM
Zhipu AI Shares Rise After Lockup Expiry Amid Investor Support
8 Jul · 8:25 PM